Immunogenicity and autoimmunity during anti-TNF therapy.

The introduction of anti-tumour necrosis factor (TNF) agents for the treatment of rheumatoid arthritis (RA), Crohn's disease (CD) or spondyloarthritis (SpA) has revolutionised the therapeutic approach to patients with active disease failing to respond to conventional therapy. However, some of the patients treated with selective TNF inhibitors may develop autoantibodies, such as antinuclear antibodies (ANAs) and anti-double-stranded DNA (anti-dsDNA) antibodies. Furthermore, anti-phospholipid antibodies, which are mainly detected by means of anti-cardiolipin assays, have been found in RA patients receiving TNF blockers. There have also been a number of reports of the development of anti-drug antibodies, of which those against infliximab can interfere with the drug's pharmacokinetics (and therefore its effects), and may also cause acute and delayed infusion and injection site reactions. The onset of autoimmune diseases during biological treatment is rare, but it needs to be promptly recognised in order to plan appropriate patient management. The addition of an immunosuppressive drug can reduce the induction of anti-TNF antibodies.

[1]  E. Kuipers,et al.  Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease , 2008, Alimentary pharmacology & therapeutics.

[2]  P. V. van Riel,et al.  Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study , 2012, BMC Musculoskeletal Disorders.

[3]  P. Baiardi,et al.  Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFα blocking agents in rheumatoid arthritis , 2007, Clinical Rheumatology.

[4]  W. Sandborn,et al.  Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.

[5]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[6]  M. Khamashta,et al.  Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases , 2007, Medicine.

[7]  M. Feldmann,et al.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.

[8]  L. Klareskog,et al.  Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies , 2004, Annals of the rheumatic diseases.

[9]  M. Peppercorn,et al.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.

[10]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[11]  E. Bonfá,et al.  Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases , 2010, Clinical reviews in allergy & immunology.

[12]  P. Sarzi-Puttini,et al.  Autoantibody production in patients treated with anti-TNF-α , 2008, Expert review of clinical immunology.

[13]  M. Khamashta,et al.  Autoimmune diseases induced by biological agents: a double-edged sword? , 2010, Autoimmunity reviews.

[14]  K. Heeg,et al.  DNA activates human immune cells through a CpG sequence‐dependent manner , 1999, Immunology.

[15]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[16]  F. Breedveld,et al.  An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status , 2008, Clinical Rheumatology.

[17]  E. Martı́n-Mola,et al.  Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. , 2011, Rheumatology.

[18]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  P. Sarzi-Puttini,et al.  Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. , 2009, Autoimmunity reviews.

[20]  D. Baeten,et al.  Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. , 2005, Arthritis and rheumatism.

[21]  P. Butler,et al.  Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity , 1999, Nature Medicine.

[22]  E. Veys,et al.  Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. , 2003, Arthritis and rheumatism.

[23]  P. Sarzi-Puttini,et al.  Anti-cytokine antibodies for rheumatic diseases. , 2009, Current opinion in investigational drugs.

[24]  S. Travis,et al.  Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review , 2009, Inflammatory bowel diseases.

[25]  K. Bendtzen,et al.  Can Measurements of Anti-Infliximab Antibodies Predict Acute Severe Infusion Reactions to Infliximab? , 2011 .

[26]  K. Bendtzen,et al.  Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease , 2008, The American Journal of Gastroenterology.

[27]  P. Sarzi-Puttini,et al.  Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study , 2005, Arthritis research & therapy.

[28]  W. Sandborn,et al.  Crohn's disease , 2012, The Lancet.

[29]  A. Matucci,et al.  Anti‐infliximab IgE and non‐IgE antibodies and induction of infusion‐related severe anaphylactic reactions , 2010, Allergy.

[30]  K. Bendtzen,et al.  Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies , 2009, Scandinavian journal of gastroenterology.

[31]  S. Hanauer,et al.  Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial , 2007, Gut.

[32]  P. Sarzi-Puttini,et al.  Different effects of biological drugs in rheumatoid arthritis. , 2013, Autoimmunity reviews.

[33]  H. Amital,et al.  Anti-TNF therapy: safety aspects of taking the risk. , 2011, Autoimmunity reviews.

[34]  L. Klareskog,et al.  Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. , 2005, Arthritis and rheumatism.

[35]  M. Dougados,et al.  Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. , 2011, Clinical and experimental rheumatology.

[36]  J. Gisbert,et al.  Systematic review: antibodies and anti‐TNF‐α levels in inflammatory bowel disease , 2012, Alimentary pharmacology & therapeutics.

[37]  A. Dall'aglio,et al.  Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis , 2007, Rheumatology International.

[38]  M. Bala,et al.  Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[39]  G. Ferraccioli,et al.  Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections , 2002, Annals of the rheumatic diseases.

[40]  F. Caprioli,et al.  Cytokine therapies in Crohn's disease: where are we now and where should we go? , 2011, Inflammation & Allergy - Drug Targets.

[41]  F. Armbruster,et al.  Immunogenicity, efficacy and adverse events of adalimumab in RA patients , 2006, Rheumatology International.

[42]  G. Porro,et al.  Autoantibody profile during short‐term infliximab treatment for Crohn's disease: a prospective cohort study , 2005, Alimentary pharmacology & therapeutics.